Mrs Amanda Gilkes

2024

• Russell, N. H. et al. 2024. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations. Journal of Clinical Oncology 42(10), pp. 1158-1168. (10.1200/JCO.23.00943)

2023

• Othman, J. et al. 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7(16), pp. 4539-4549. (10.1182/bloodadvances.2023010276)
• Othman, J. et al. 2023. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia 37(10), pp. 2066-2072. (10.1038/s41375-023-01994-x)
• Othman, J. et al. 2023. Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood 141(15), pp. 1846-1857. (10.1182/blood.2022018108)
• Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37, pp. 276-287. (10.1038/s41375-022-01801-z)

2022

• Loo, S. et al. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter]. Blood 140(22), pp. 2407-2411. (10.1182/blood.2022016567)
• Russell, N. H. et al. 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140(S1), pp. 526-528. (10.1182/blood-2022-162377)
• Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
• Döhner, K. et al. 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140(S1), pp. 6293-6294. (10.1182/blood-2022-159212)
• Othman, J. et al. 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition, New Orleans, Louisiana, 10-13 December 2022, Vol. 140. Vol. S1. American Society of Hematology pp. 1036-1038., (10.1182/blood-2022-159433)
• Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
• Menezes, A. C. et al. 2022. Increased expression of RUNX3 inhibits normal human myeloid development. Leukemia 36, pp. 1769-1780. (10.1038/s41375-022-01577-2)
• Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12, article number: 840046. (10.3389/fonc.2022.840046)
• Coats, T. et al. 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196(6), pp. 1337-1343. (10.1111/bjh.18013)
• Menezes, A. C. et al. 2022. RUNX3 overexpression inhibits normal human erythroid development. Scientific Reports 12, article number: 1243. (10.1038/s41598-022-05371-z)

2021

• Dennis, M. et al. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5(24), pp. 5621-5625. (10.1182/bloodadvances.2021005038)
• Tiong, I. S. et al. 2021. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances 5(23), pp. 5107-5111. (10.1182/bloodadvances.2021005455)
• Lin, W. et al. 2021. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications 12(1), article number: 6233. (10.1038/s41467-021-26551-x)
• Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193(1), pp. 155-159. (10.1111/bjh.17125)
• Kingshott, G. et al. 2021. Alteration of metabolic conditions impacts the regulation of IGF-II/H19 imprinting status in prostate cancer. Cancers 13(4), article number: 825. (10.3390/cancers13040825)

2020

• Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34(2), pp. 427-440. (10.1038/s41375-019-0596-4)

2018

• Freeman, S. D. et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)

2017

• Khan, N. et al. 2017. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31, pp. 1059-1068. (10.1038/leu.2016.309)
• Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)

2016

• Ivey, A. et al. 2016. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine 374(5), pp. 422-433. (10.1056/NEJMoa1507471)

2015

• Kuhnl, A. et al. 2015. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood 125(19), pp. 2985-2994. (10.1182/blood-2014-12-613703)
• Ostronoff, F. et al. 2015. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council report. Journal of Clinical Oncology 33(10), pp. 1157-1164. (10.1200/JCO.2014.58.0571)

2014

• Lazenby, M., Gilkes, A., Marrin, C., Evans, A., Hills, R. K. and Burnett, A. K. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28, pp. 1953-1959. (10.1038/leu.2014.90)

2012

• Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120(21), article number: 1281.

2011

• Mohamedali, A. M. et al. 2011. Single Nucleotide Polymorphism Array (SNP-A) karyotype is the best predictor of prognosis in normal cytogenetics Acute Myeloid Leukaemia (AML). Blood -New York- 118(21), pp. 188-189.
• Goardon, N. et al. 2011. Coexistence Of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19(1), pp. 138-152. (10.1016/j.ccr.2010.12.012)

2010

• Mohamedali, A. et al. 2010. Prognostic significance of cryptic genomic aberrations in AML with normal karyotype [Abstract]. Blood 116(21), pp. 1125.
• Burnett, A. K. et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115(5), pp. 948-956. (10.1182/blood-2009-08-236588)
• Burnett, A. K. et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115(5), pp. 948-956. (10.1182/blood-2009-08-236588)

2009

• McLornan, P. et al. 2009. The prognostic role of C-Flip in AML [Abstract]. Haematologica 94(S2), pp. 108.

2008

• Gale, R. et al. 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112(11), pp. 207-207.
• Al Shaer, L. et al. 2008. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. British Journal of Haematology 141(4), pp. 483-493. (10.1111/j.1365-2141.2008.07053.x)
• Jenkins, C. et al. 2008. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. British Journal of Haematology 143(5), pp. 661-671. (10.1111/j.1365-2141.2008.07392.x)
• Guy, C., Gilkes, A. F., Gale, R., Linch, D. C., Hills, R. K. and Burnett, A. K. 2008. The impact of MN1 over-expression on the outcome of younger patients with AML treated with intensive chemotherapy with or without ATRA therapy [Abstract]. Blood -New York- 112(11), pp. 1023-1023.

2007

• Tonks, A., Pearn, L., Musson, M., Gilkes, A. F., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21(12), pp. 2495-2505. (10.1038/sj.leu.2404961)
• Walsby, E. J., Gilkes, A. F., Tonks, A., Darley, R. L. and Mills, K. I. 2007. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139(1), pp. 94-97. (10.1111/j.1365-2141.2007.06756.x)

2006

• Knapper, S., Mills, K. I., Gilkes, A. F., Austin, S. J., Walsh, V. and Burnett, A. K. 2006. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108(10), pp. 3494-3503. (10.1182/blood-2006-04-015487)
• Guinn, B., Gilkes, A. F., Mufti, G. J., Burnett, A. K. and Mills, K. I. 2006. The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. British Journal of Haematology 134(2), pp. 238-239. (10.1111/j.1365-2141.2006.06135.x)

2005

• Guinn, B. et al. 2005. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications 333(3), pp. 703-713. (10.1016/j.bbrc.2005.05.161)
• Gale, R. E. et al. 2005. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106(12), pp. 3768-3776. (10.1182/blood-2005-04-1746)

2000

• Guinn, B. A., Evely, R. S., Walsh, V., Gilkes, A., Burnett, A. K. and Mills, K. I. 2000. An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells. Leukemia and Lymphoma 37(3-4), pp. 393-404. (10.3109/10428190009089440)
• Mills, K. I. et al. 2000. High FUS/TLS expression in acute myeloid leukaemia samples. British Journal of Haematology 108(2), pp. 316-321. (10.1046/j.1365-2141.2000.01883.x)

1999

• Mills, K. I., Woodgate, L., Gilkes, A. F., Walsh, V., Sweeney, M. C., Brown, G. and Burnett, A. K. 1999. Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. Biochemical and Biophysical Research Communications 263(2), pp. 294-300. (10.1006/bbrc.1999.1356)
• Mills, K. I., Walsh, V., Gilkes, A. F., Woodgate, L. J. and Burnett, A. K. 1999. Inhibitors of mitochondrial function in HL60 cells induce CD14 prior to CD38 [Abstract]. British Journal of Haematology 105(Sup.1), pp. 77.
• Woodgate, L. J., Walker, E. J., Gilkes, A. F., Walsh, V., Sweeney, M. C., Mills, K. I. and Burnett, A. 1999. Lovastatin in combination with ATRA may be a potential therapy for leukaemia [Abstract]. British Journal of Haematology 105(Sup.), pp. 74.
• Robinson, L. G. et al. 1999. Altered gene expression in 32D cells expressing the AML1A gene or AML1-ETO fusion gene. British Journal of Haematology 105(Supp1), pp. 103-103.

1998

• Mills, K. I. et al. 1998. Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Letters 440(1-2), pp. 158-162. (10.1016/s0014-5793(98)01435-5)
• Mills, K. I., Walsh, V., Gilkes, A., Woodgate, L., Brown, G. and Burnett, A. K. 1998. Identification of transcription factors expressed during ATRA-induced neutrophil differentiation of HL60 cells. British Journal of Haematology 103(1), pp. 87-92. (10.1046/j.1365-2141.1998.00947.x)
• Woodgate, L. J., Walker, E. J., Gilkes, A. F., Walsh, V., Mills, K. I. and Burnett, A. K. 1998. Lovastatin in combination with ATRA partially overcomes the block in ATRA responsiveness of the serum independent HL60 cell line [Abstract]. British Journal of Haematology 101(S), pp. 34.
• Woodgate, L. J., Gilkes, A. F., Newsway, V., Mills, K. I. and Burnett, A. K. 1998. Mitochondrial inhibitors may act as promoters of differentiation in the serum free HL60 cell line [Abstract]. British Journal of Haematology 101(S), pp. 34.

1997

• Mills, K. et al. 1997. Increased tissue infiltration and decreased survival of SCID mice injected with 32D cells expressing BCR-ABL mRNA may be related to increased expression of CD44 and RHAMM [Abstract]. Blood 90(10), pp. 4005.
• Woodgate, L., Gilkes, A. F., Newsway, V., Mills, K. I. and Burnett, A. K. 1997. Mitochondrial inhibitors as differentiation agents in the myeloid HL60 cell line [Abstract]. Blood 90(10), pp. 3801.

1996

• Evely, R. S., Darley, R. L., Gilkes, A. F., Goringe, A., Mirza, T. and Burnett, A. K. 1996. In-vivo modelling of myeloid malignancies using severe combined immunodeficient (SCID) mice [Abstract]. British Journal of Haematology 93, pp. 205.